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Abstract
Background: This study was performed to investigate the effect of microRNA-203 (miR-203) and ΔNp63 on cell
proliferation and the functional connection between miR-203 and ΔNp63 in ESCC.
Methods: We employed 2 human ESCC cell lines, Eca109 and TE-1, as the model system. The effect of miR-203
and ΔNp63 on cell proliferation was determined in cells transfected with miR-203 mimic and ΔNp63 small
interfering RNA (siRNA), respectively. The regulation of ΔNp63 expression in ESCC cells by miR-203 was studied by
luciferase reporter assay, RT-PCR and western blot analysis in cells transfected with miR-203. The effect of ΔNp63 re-
expression on miR-203 induced inhibition of cell proliferation was studied by cell proliferation assay in cells
cotransfected with miR-203 and pcDNA-ΔNp63 plasmid (without the 3’-UTR of ΔNp63).
Results: We found that both miR-203 and ΔNp63 siRNA signicantly inhibited cell proliferation in ESCC. MiR-203
could down-regulate endogenous ΔNp63 expression at the posttranscriptional level. Moreover, re-expression of
ΔNp63 in cells transfected with miR-203 significantly attenuated the miR-203 induced inhibition of cell proliferation.
Conclusions: Our data implied that miR-203 could inhibit cell proliferation in human ESCC through ΔNp63-
mediated signal pathway. Therefore, we propose that miR-203 might be used as a therapeutic agent for human
ESCC.
Background
Esophageal cancer is one of the most lethal human
cancers mainly located in China, Japan, and southeast
Africa [1]. According to the etiologic and pathologic
characteristics, it could be divided into two main forms,
esophageal squamous cell carcinoma (ESCC) and eso-
phageal adenocarcinoma (EAC). Previous reports
showed that the incidence of ESCC is much higher than
that of EAC in the above mentioned areas [1,2], and the
5-year survival rate of ESCC after surgery ranges from
14% - 22% [3,4]. Much effort has been spent on the
study of the biological behavior of ESCC cells to develop
effective treatment strategies. Although some oncogenes
and tumor suppressor genes were reported to be asso-
ciated with the development of ESCC [5-7], few specific
molecules regulating the initiation and progression of
ESCC have been identified. Conceivably, elucidation of
the molecular pathways involved in the cell proliferation
of ESCC will provide important clues for the develop-
ment and evaluation of novel anticancer therapies.
MicroRNAs, a class of small non-coding RNAs, have
been identified as a new kind of gene expression regula-
tors through targeting the 3’-untranslated region (UTR)
of mRNAs for translational repression, degradation or
both [8-10]. In the recent years, mounting data suggest
that microRNAs are involved in essential tumor cell bio-
logical processes, such as proliferation, invasion, and
apoptosis [9,11,12].
It was reported that MicroRNA-203 (miR-203) located
in a region at chromosome 14 [13], which contains a
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known human microRNA gene), exhibited significantly
down-regulated expression in some tumors such as head
and neck squamous cell carcinomas [14], hematopoietic
malignancy [13] and colon cancer [15]. Subsequent stu-
dies showed that the expression level of miR-203 is
inversely correlated with the capacity of cell prolifera-
tion in human head and neck squamous cell carcinoma
[14], hepatocellular carcinoma [16], chronic myelogen-
ous leukemia and B cell leukemia [13]. In addition,
ΔNp63, an important oncogene regulating cell prolifera-
tion in some tumors [17], was recently identified as a
target gene of miR-203 in human epithelial precursor
cells, as well as human head and neck squamous cell
carcinoma cells [14,18]. These findings suggested that
there might be a functional connection between miR-
203 and ΔNp63 in cell proliferation regulation.
In human ESCC, genome-wide microRNA expression
profile assay showed that the expression level of miR-
203 was significantly down-regulated in tumor tissue
compared with the matched normal tissue [19-21]. In
contrast, the expression level of ΔNp63 was significantly
higher in tumor tissue than in the matched normal tis-
sue [22,23]. However, the effect of miR-203 and ΔNp63
on the proliferation of ESCC cells, as well as the func-
tional relationship between miR-203 and ΔNp63 in
ESCC cells has not been documented. Since certain
microRNAs may show different functions in different
type of tumors [24], the role of miR-203 in the regula-
tion of cell proliferation of ESCC warrants investigation.
In light of the previous reports, we hypothesized that
miR-203 might regulate the proliferation of ESCC cells
through the ΔNp63-mediated signal pathway. Therefore,
using 2 human ESCC cell lines (Eca109 and TE-1) as a
model system, here we set out to investigate the effect
of miR-203 and ΔNp63 on the proliferation of ESCC
cell, as well as the regulation of the expression of
ΔNp63 by miR-203 in ESCC. Our results suggest that
miR-203 may inhibit the cell proliferation in ESCC
through the ΔNp63-mediated signal pathway.
Methods
Cell culture
Human ESCC cell lines Eca109 and TE-1 were pur-
chased from the Shanghai Institute of Biochemistry and
Cell Biology (Shanghai, China). Cells were maintained in
RPMI1640 (Invitrogen) supplemented with 10% fetal
bovine serum (Invitrogen), 100 U/ml penicillin and 100
μg/ml streptomycin, within a humidified atmosphere
containing 5% CO2 at 37°C.
Cell transfection
1×1 0
6 cells cultured in a well of 6-well cell culture
plate were transiently transfected with 50 pmol of
miR-203 double-stranded mimics (or control microRNA)
and ΔNp63 siRNA oligonucleotide duplexes (or control
siRNA) using Lipofectamine 2000 (Invitrogen) according
to the manufacturer’s protocol, respectively. Transfection
efficiency was optimized using 6-carboxyfluorescein-
labeled microRNA (or siRNA) at approximately 80% in
Eca109 and TE-1 cells.
The sequences of miR-203 were:
Sense: 5’-GUGAAAUGUUUAGGACCACUAG-3’,
Anti-sense: 5’-CUAGUGGUCCUAAACAUUUCAC-3’,
A scrambled microRNA with no homology to any
known human microRNA was used as negative control:
Sense: 5’-GUUGAACUGUUAAGAACCACUGG-3’,
Anti-sense: 5’-CCAGUGGUUCUUAACAGUUCAAC-3’,
The siRNA oligonucleotides targeting ΔNp63 were
designed as previously described [25]:
Sense: 5’-AACAGCCAUGCCCAGUAUGUA-3’;
Anti-sense: 5’- UACAUACUGGGCAUGGCUGUU-3’.
A scrambled siRNA with no homology to any known
human mRNA was used as negative control:
Sense: 5’-CCCUGUUAAAAAUCCAGGCGA-3’;
Anti-sense: 5’-UCGCCUGGAUUUUUAACAGGG-3’.
All microRNA mimics or siRNA oligonucleotide
duplexes were synthesized by Genephama Biotech
(Shanghai, China).
Quantitative Reverse Transcriptase Polymerase Chain
Reaction (qRT-PCR)
Total RNA was extracted from 1 × 10
5 cells using the
RNeasy RNA Mini Kit (Qiagen). First strand cDNA was
synthesized using powerscipt reverse transcriptase
(Clontech). The following gene-specific primer pairs
were used for quantitative PCR:
ΔNp63: Forward, 5’-GGGTGAGCGTGTTATT-
GATGCT-3’;
Reverse, 5’-GAGTGGAATGACTTCAACTTT-3’.
GAPDH:F o r w a r d ,5 ’-GCTGAGTATGTCGTGGA
GTC-3’;
Reverse, 5’-AGTTGGTGGTGCAGGATGC-3’.
PCR was performed using a Fast Start Master SYBR
Green Kit (Roche) on a LightCycler (Roche). The
expression level of ΔNp63 mRNA was analyzed using
RealQuant software (Roche) and normalized to that of
GAPDH mRNA.
Western blot
Cellular proteins were prepared using cell lysis buffer
(50 mM Tris-HCl, pH 8.0, 1% NP-40, 2 mM EDTA,
10 mM NaCl, 2 mg/ml aprotinin, 5 mg/ml leupeptin,
2m g / m lp e p s t a t i n ,1m MD T T ,0 . 1 %S D Sa n d1m M
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Page 2 of 10phenylmethylsulfonyl fluoride). Equal amounts of pro-
tein (50 μg) were separated by 10% SDS PAGE and then
transferred to nitrocellulose membranes (NY, USA) by
electroblotting. The membranes were blocked with 5%
BSA in TBST (10 mM Tris-HCl, pH 8.0, 150 mM NaCl,
and 0.05% Tween 20) for 1 hr, and then incubated with
mouse anti-human ΔNp63 antibody (Santa Cruz) over-
night at 4°C before subsequent incubation with horse-
radish peroxidase-conjugated goat anti-mouse antibody
(BD) for 1 hr at 37°C. Protein was visualized using
enhanced chemiluminescence reagent (Santa Cruz). The
expression level of ΔNp63 protein was analyzed using
LabWork 4.0 program (UVP) and normalized to that of
b-actin protein.
Clonogenic assay
Single-cell suspension was prepared using trypsin treat-
ment. Cells were then seeded into 6-well cell culture
plates (200 cells/well) and incubated for 2 weeks at
37°C. Then, cells were washed twice with PBS and
stained with a mixture of 6.0% glutaraldehyde and 0.5%
crystal violet for 1 hour at 37°C. The plates were air-
d r i e da tr o o mt e m p e r a t u r e .C olony forming efficiency
was calculated as the percentage of plated cells that
formed colonies.
Cell population doubling time
Cells were plated into 6-well plates (1 × 10
4 cells/well)
and cultured at 37°C. Cell population doubling time
(PDT) was calculated using the following equation: PDT
( h r )=( l o g 2×t ) / ( l o g N t -l o g N 0) ,w h e r et=t i m ei nc u l -
ture (hr), Nt = final cell count, N0 = original cell count.
Cell cycle assay
Cells were fixed in 70% ethanol for 2 hr at 4°C. After
washing with PBS, cells were treated with RNaseA
(50 μg/ml) and stained with propidium iodide (25 μg/ml)
for 30 min at 37°C. Samples were analyzed using an
FACSCalibur flow cytometer (BD Biosciences) and dis-
tribution of cell-cycle phases was determined using
Modfit Software (BD Biosciences). The proliferative
index was calculated as the percentage of cells in S/G2/
M-phase.
Apoptosis assay
Cells were stained with annexin V-FITC and propidium
iodide using the ANNEXIN V-FITC Kit (Beckman)
according to the manufacturer’s protocol and subjected
to flow cytometric analysis. Viable cells were unstained
by annexin V or propidium iodide, early apoptotic cells
were stained by annexin V but not propidium iodide,
and late apoptotic cells were stained by annexin V and
propidium iodide. The apoptotic index was calculated as
the percentage of annexin V
+/propidium iodide
- cells.
Luciferase reporter assay
The full-length 3’-UTR of ΔNp63 mRNA containing the
miR-203 binding site was amplified by PCR (Forward:
5’-ggggagctcatataagaactcttgcagtct-3’;R e v e r s e :5 ’-
gggaagcttggtgtacattcttctagaac-3’). Mutant ΔNp63 3’-
UTR, which carried a substitution of four nucleotides
(CTTT to GAAA) within the core binding sites of
ΔNp63 3’-UTR (14), was obtained using overlapping
extension PCR. Normal (or mutant) ΔNp63 3’-UTR was
cloned into the SacI-HindIII site of the pMIR-REPORT
luciferase vector (Biosystems) and named as Luc-ΔNp63
(or Luc-ΔNp63-mut). Then, 1 × 10
6 cells were cotrans-
fected with 50 pmol of microRNA-203 (or control
microRNA), 1 μgo fL u c - ΔNp63 (or Luc-ΔNp63-mut)
plasmid, and 1 μg of pMIR-REPORT b-Gal vector using
Lipofectamine 2000. The Luciferase activity was exam-
ined at 48 hr posttransfection using the luciferase assay
kit (Clontech) and normalized to b-galactosidase
activity.
Statistical Analyses
Data are presented as mean ± SEM. Statistical signifi-
cance was tested using SPSS11.0 software, using t tests
for 2-group comparisons. A P value less than 0.05 is
considered statistically significant.
Results
MiR-203 could inhibit the proliferation of ESCC cell lines
We scanned the basal expression levels of miR-203 in
the ESCC cell lines by real time PCR. It was found
that both Eca109 and TE-1 expressed very low level of
miR-203 (Additional file 1, Figure S1). Therefore, we
investigated the effect of miR-203 on cell proliferation
using cells transfected with miR-203 (or control
microRNA). As shown in Figure S1, mature miR-203
was highly expressed in cells transfected with miR-203
while the expression level of miR-203 was still very
low in cells transfected with control microRNA 48 hr
posttransfection. In addition, cells treated with miR-
203 had a significantly lower proliferative index and a
significantly higher apoptotic index than cells trans-
fected with control microRNA (Figure 1A-C and
Additional file 1, Table. S1). Meanwhile, cells trans-
fected with miR-203 exhibited significantly lower
colony forming efficiency as well as significantly
longer population doubling time than those trans-
fected with control microRNA (Figure 1D-F). These
results suggest that miR-203 could inhibit the prolif-
eration of ESCC cell.
Repressing ΔNp63 expression could inhibit the
proliferation of ESCC cell
To investigate the effect of ΔNp63 on the proliferation
of ESCC cell, we evaluated the cell proliferative capacity
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Page 3 of 10Figure 1 MiR-203 inhibits the proliferation of ESCC cell lines. (A, B) Cell cycle analysis was performed at 48 hr posttransfection by staining
DNA with propidium iodide prior to flow cytometry. Results showed that proliferative index (PI) of cells transfected with miR-203 was
significantly lower than that of cells transfected with control microRNA. (C, D) Apoptosis assay was performed at 48 hr posttransfection by
staining cells with annexin V-FITC and propidium iodide prior to flow cytometry. Results showed that apoptotic index (AI) of cells transfected
with miR-203 was significantly higher than that of cells transfected with control microRNA. (E, F) Clonogenic assay was performed as described
in materials and methods with cells at 24 hr posttransfection. Results showed that the colony forming efficiency (CFE) of cells transfected with
miR-203 was significantly lower than that of cells transfected with control microRNA. (G) Cell population doubling time (PDT) was determined as
described in materials and methods with cells at 24 hr posttransfection. Results showed that the PDT of cells transfected with miR-203 was
significantly longer than that of cells transfected with control microRNA. Transfection condition: Cells (1 × 10
6) of Eca109 and TE-1 were
transfected with 50 pmol of miR-203 (or control microRNA). Data represent mean ± SEM from 4 independent experiments; *, P < 0.05 by t test.
**, P < 0.01 by t test.
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Page 4 of 10of cells (Eca109 and TE-1) transfected with ΔNp63
siRNA (or control siRNA). At 48 hr posttransfection,
the expression of ΔNp63 protein and mRNA in the cells
transfected with ΔNp63 siRNA was significantly
decreased in comparison with that of cells transfected
with control siRNA (Figure 2A-C), indicating that the
expression of ΔNp63 was effectively inhibited by ΔNp63
siRNA. Subsequent studies showed that the proliferative
capacity of cells transfected with ΔNp63 siRNA was sig-
nificantly lower than that of cells treated with control
siRNA. As shown in Figure 2d and 2e, cells transfected
with ΔNp63 siRNA showed a significantly lower prolif-
erative index as well as a significantly higher apoptotic
index than those cells treated with control siRNA.
Meanwhile, cells transfected with ΔNp63 siRNA exhib-
ited a significantly lower colony forming efficiency as
well as a significantly longer population doubling time
than the control cells (Figure 2F and 2G). These results
imply that repressing ΔNp63 expression could inhibit
the proliferation of ESCC cell.
MiR-203 posttranscriptionally down-regulates ΔNp63
expression by targeting the 3’ untranslated region of
ΔNp63
It was reported that the 3’-UTR of ΔNp63 contains the
miR-203 binding site [14]. To determine whether the 3’-
UTR of ΔNp63 mRNA is a functional target of miR-203
in ESCC cells, we evaluated the reporter activity in cells
cotransfected with miR-203 (or control microRNA) and
Luc-ΔNp63 plasmid (or Luc-ΔNp63-mut plasmid). As
shown in Figure 3A, cells cotransfected with miR-203
and Luc-ΔN p 6 3p l a s m i ds h o w e das i g n i f i c a n td e c r e a s e
of reporter activity in comparison with those cotrans-
fected with the control microRNA and Luc-ΔNp63 plas-
mid. However, cells cotransfected with miR-203 and
Luc-ΔNp63-mut plasmid showed no significant differ-
ence in reporter activity as compared with cells cotrans-
fected with control microRNA and Luc-ΔNp63-mut
plasmid (Figure 3B).
We further detected the expression of ΔNp63 pro-
tein and mRNA by western blot and qRT-PCR in
Eca109 and TE-1 cells transfected with miR-203 (or
control microRNA). As shown in Figure 3C and 3D,
the expression of ΔNp63 protein was decreased by
approximately 80% in cells transfected with miR-203 as
compared to the cells treated with control microRNA
at 48 hr posttransfection (0.08 ± 0.02 vs. 0.62 ± 0.10
for Eca109, P < 0.05; 0.13 ± 0.03 vs. 0.80 ± 0.11 for
TE-1, P < 0.05). However, the expression of ΔNp63
mRNA showed no significant difference between the
2 groups (Figure 3E). These results indicate that the
3’-UTR of ΔNp63 mRNA is a functional target of
miR-203 in ESCC cells.
The inhibition of the proliferation of ESCC cells by miR-
203 could be significantly attenuated by the re-
expressing of ΔNp63
To investigate the functional connection between miR-
203 and ΔNp63 in the regulation of ESCC cell prolifera-
tion, we further evaluated the proliferative capacity of
cells cotransfected with miR-203 and pcDNA-ΔNp63 (or
empty pcDNA) plasmid. Notably, the pcDNA-ΔNp63
plasmid was designed to carry the open reading frame of
human ΔNp63 without 3’-UTR. At 48 hr posttransfec-
tion, western blot revealed that the expression level of
ΔNp63 in cells cotransfected with miR-203 and pcDNA-
ΔNp63 plasmid was significantly higher than that in cells
cotransfected with miR-203 and empty pcDNA plasmid
(Figure 4A and 4B). Subsequent studies showed that the
cells cotransfected with miR-203 and pcDNA-ΔNp63
plasmid had a significantly higher proliferative index, as
well as a significantly lower apoptotic index than those
cotransfected with miR-203 and empty pcDNA plasmid
(Figure 4C and 4D). Meanwhile, cells cotransfected with
miR-203 and pcDNA-ΔNp63 plasmid exhibited a signifi-
cantly higher colony forming efficiency, as well as a sig-
nificantly shorter population doubling time than the
control cells (Figure 4E and 4F). These results imply that
re-expressing ΔNp63 could significantly attenuate the
inhibitory effect of miR-203 on cell proliferation, suggest-
ing that the miR-203 inhibits the proliferation of ESCC
cells through the ΔNp63-mediated signal pathway.
Discussion
It was known that microRNAs could regulate a variety of
cellular pathways by affecting the expression of multiple
types of target genes and the alteration of microRNAs
expression might contribute to human carcinogenesis
[9,11,12]. Thus, an understanding of the specific micro-
RNAs involved in the process of tumor development
would provide valuable insight for the diagnosis
and treatment of patients with tumor. Here, we have
demonstrated that miR-203 could down-regulate the
proliferation of ESCC cells, probably through the
ΔNp63-mediated signal pathway. Our data suggest that
re-expressing miR-203 might benefit the treatment of
ESCC.
It was reported that the expression of miR-203 was sig-
nificantly down-regulated in some tumors, including
head and neck squamous cell carcinomas [14], hemato-
poietic malignancy [13] and colon cancer [15]. Moreover,
it was reported that inhibition of miR-203 expression
could significantly increase the proliferation of Hela cells
[26], whilst re-expression of miR-203 could inhibit the
proliferative capacity of cells in human head and neck
squamous cell carcinoma [14], hepatocellular carcinoma
[16], chronic myelogenous leukemia and B cell leukemia
Yuan et al. BMC Cancer 2011, 11:57
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Page 5 of 10[13]. These findings suggest that miR-203 might function
as a tumor suppressor gene in a variety of tumors. In the
case of esophageal cancer, genome-wide microRNA
expression profile analysis revealed that the expression
level of miR-203 was 2- to 10-fold lower in tumor than in
the matched normal tissues [19-21]. However, the effect
of miR-203 on the cell proliferation in human ESCC has
not been reported. In the present study, we found that
the proliferative capacity of ESCC cells transfected with
miR-203 was significantly lower than that of cells trans-
fected with control microRNA, suggesting that miR-203
could inhibit the proliferative capacity of ESCC cells.
Figure 2 Repressing ΔNp63 expression inhibits proliferation of ESCC cell lines. (A, B) The expression level of ΔNp63 protein was detected
by Western Blot at 48 hr posttransfection and normalized to that of b-actin. Results showed that the expression of ΔNp63 protein was
significantly decreased in cells transfected with ΔNp63 siRNA as compared to those transfected with control siRNA. (C) The expression level of
ΔNp63 mRNA was detected by qRT-PCR at 48 hr posttransfection and normalized to that of GAPDH. Results showed that the expression of ΔNp63
mRNA was significantly decreased in cells transfected with ΔNp63 siRNA as compared to those transfected with control siRNA. (D-G) Cell
proliferation was evaluated by cell cycle analysis (D), annexin V-FITC/propidium iodide double staining (E), population doubling time
determination (F), and clonogenic assay (G) as described in materials and methods. Results showed that the proliferative capacity of cells
transfected with ΔNp63 siRNA was significantly lower than that of cells transfected with control siRNA. Transfection condition: Cells (1 × 10
6)o f
Eca109 and TE-1 were transfected with 50 pmol of ΔNp63 siRNA (or control siRNA). Data represent mean ± SEM from 4 independent
experiments; *, P < 0.05 by t test. **, P < 0.01 by t test.
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Page 6 of 10Previous studies indicated that ΔNp63, an alternative
splice variant of p63 gene lacking TA domain [17], is
the major isotype expressed in a variety of human squa-
mous cell carcinoma including ESCC [27], and that the
expression level of ΔNp63 in tumor tissues was signifi-
cantly higher than in the matched normal tissues
[22,27]. In our pilot study, we found ΔNp63 was highly
expressed, whilst TAp63 was hardly detectable in
Eca109 and TE-1 (Additional file 1, Figure S2). Here, we
demonstrated that repressing ΔNp63 expression by
siRNA could significantly inhibit the proliferation of
ESCC cell lines, implying that ΔNp63 played a positive
role in ESCC cell proliferation. Our findings, in
combination with the previous reports that ΔNp63
could promote the cell proliferation in head and neck
squamous cell carcinoma [14] as well as lung squamous
cell carcinoma [27], suggest that ΔNp63 may function
as an oncogene in human squamous cell carcinoma.
Recently, using bioinformatic analysis, Lena et al. [14]
and Yi et al. [18] independently reported that the 3’-
UTR of ΔNp63 contain the miR-203 binding site. Subse-
quent studies showed that miR-203 could repress the
expression of ΔNp63 and inhibit cell proliferation in
human epithelial precursor cells as well as human head
and neck squamous cell carcinoma cells, suggesting that
miR-203 is a key molecule controlling the ΔNp63-
Figure 3 MiR-203 posttranscriptionally regulates ΔNp63 expression by targeting the 3’-UTR of ΔNp63. (A, B) 1×1 0
6 cells (Eca109 or TE-
1) were cotransfected with 50 pmol of miR-203 (or control microRNA) and 1 μg of Luc-ΔNp63 (or Luc-ΔNp63-mut) plasmid, respectively.
Luciferase reporter assay were performed at 48 hr posttransfection. Results showed that cells cotransfected with miR-203 and Luc-ΔNp63 plasmid
exhibited a significant decrease of reporter activity in comparison with those cotransfected with the control microRNA and Luc-ΔNp63 plasmid
(a). However, the reporter activity of cells cotransfected with miR-203 and Luc-ΔNp63-mut plasmid showed no significant difference with that of
cells cotransfected with control microRNA and Luc-ΔNp63-mut plasmid (b). (C, D) Cells (1 × 10
6) of Eca109 and TE-1 were transfected with 50
pmol of miR-203 (or control microRNA), respectively. The expression level of ΔNp63 protein was detected by Western Blot at 48 hr
posttransfection and normalized to that of b-actin. Results showed that the level of ΔNp63 protein was significantly decreased in cells
transfected with miR-203 as compared to the cells transfected with control microRNA. Results showed that the expression level of ΔNp63 protein
was significantly decreased in cells transfected with miR-203 as compared to the cells transfected with control microRNA. (E) Cells (1 × 10
6)o f
Eca109 and TE-1 were transfected with 50 pmol of miR-203 (or control microRNA), respectively. The expression level of ΔNp63 mRNA was
detected by qRT-PCR at 48 hr posttransfection and normalized to that of GAPDH. Results showed that the expression level of ΔNp63 mRNA
exhibited no significantly difference between cells transfected with miR-203 and those transfected with control microRNA. Data represent mean
± SEM from 4 independent experiments; **, P < 0.01 by t test.
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Page 7 of 10Figure 4 Re-expressing ΔNp63 could significantly attenuate the effect of miR-203 on the inhibition of ESCC cell proliferation. (A, B)
The expression level of ΔNp63 protein was detected by Western Blot at 48 hr posttransfection and normalized to that of b-actin. Results showed
that the expression level of ΔNp63 protein was significantly higher in cells cotransfected with miR-203 and pcDNA-ΔNp63 as compared to the
cells transfected with miR-203 and empty pcDNA. (C-F) Cell proliferation was evaluated by cell cycle analysis (C), annexin V-FITC/propidium
iodide double staining (D), population doubling time determination (E) and clonogenic assay (F) as described in materials and methods. Results
showed that the proliferative capacity of cells cotransfected with miR-203 and pcDNA-ΔNp63 was significantly higher than that of cells
cotransfected with miR-203 and empty pcDNA. Transfection condition: 1 × 10
6 cells (Eca109 or TE-1) were cotransfected with 50 pmol of miR-
203 and pcDNA-ΔNp63 (or empty pcDNA). Data represent mean ± SEM from 4 independent experiments; *, P < 0.05 by t test. **, P < 0.01 by t
test.
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cells [14,18]. However, whether miR-203 regulates the
expression of ΔNp63 in ESCC has not been identified
before. Here, we showed that miR-203 could signifi-
cantly inhibit ΔNp63 protein expression without chan-
ging the expression level of ΔNp63 mRNA, suggesting
that miR203 negatively regulated the expression of
ΔNp63 at the posttranscriptional level in ESCC. More-
over, we demonstrated that re-expressing ΔNp63 in
miR-203 transfected ESCC cells could significantly
attenuate miR-203 induced inhibition of cell prolifera-
tion. Taken together, our results suggest that miR-203
may function as a tumor suppressor by regulating
ΔNp63-mediated signal pathways in human ESCC.
However, we noticed that the proliferative capacity of
the ESCC cells cotransfected with miR-203 and pcDNA-
ΔNp63 plasmid, though much higher than that of the
cells cotransfected with miR-203 and empty pcDNA
plasmid, is still significantly lower than that of the cells
cotransfected with control microRNA and empty
pcDNA plasmid (Additional file 1, Figure S3). This
result, combined with the fact that the expression level
of ΔNp63 protein in the cells cotransfected with miR-
203 and pcDNA-ΔNp63 was significantly higher than
that in cells cotransfected with control microRNA and
empty pcDNA plasmid (Additional file 1, Figure S4),
suggest that miR-203 might regulate the proliferation of
ESCC cells through multiple target genes. In this
respect, the underlying mechanisms of miR-203 in regu-
lating the proliferation of ESCC cell warrant further
investigation.
Conclusions
In summary, we have demonstrated that miR-203 and
ΔNp63 play an important role in ESCC cell proliferation
regulation. MiR-203 can significantly inhibit the prolif-
eration of ESCC cell through the ΔNp63-mediated sig-
nal pathway. Based on these findings, we propose that
miR-203 might be used as a therapeutic agent for ESCC.
Additional material
Additional file 1: Results of the expression of miR-203, p63 isoforms
(ΔNp63 and TAp63) in Eca109 and TE-1 cell lines; the proliferative
capacity of cells cotransfected with miR-203 and pcDNA-ΔNp63
plasmid (or with control microRNA and empty pcDNA plasmid); the
expression level of ΔNp63 protein in cells cotransfected with miR-
203 and pcDNA-ΔNp63 plasmid (or with control microRNA and
empty pcDNA plasmid); cell cycle analysis of Eca109 and TE-1 cell
transfected with miR-203 and ΔNp63 siRNA.
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